Genomic Profiling Cancer Tests

The world’s most comprehensive precision oncology test to identify the most effective anti cancer treatment for your patient’s cancer.
Now available.

Read More

Immunofocus is an in-house validated IHC assay generating a tumour score that can be used as a guide to predict response to anti PD-1/PD-L1 directed therapies.

Read More

Patient Experiences

  • Want to thank all the oncologica staff that dealt with our test. Found them extremely professional, helpful and very considerate. Also test results have given me new treatment options.

  • "I was fortunate in having this test, which helped the Oncology team to tailor the Treatment to my Diagnosis".

  • "…….. recommendations in the type of drugs I should be taking, after a battle here I got onto a programme and they did a rescan of my Brain tumour last week after 4 weeks of treatment and it has reduced by 50% which is the first time in 7 months". 

  • "Just say many thanks for forwarding the report and I am pleased to say it came in time for me to be able to speak with my Consultant about the findings and this is already proving extremely helpful in planning the next stage of my treatment - extremely grateful to you and please pass on my regards to you and your team for pulling out the stops - most appreciated…"

  • "Thank you so much, you have all been absolutely incredible from start to finish, amazing…I will be writing a massive review…thanks again" 

  • "My wife is now on a targeted therapy programme rather than chemo or radiation. She is doing great, you helped save her life, thanks"

  • "…No you were not just doing your job... you guided us to get the sample to Oncologica and 'went the extra mile' to get the

    sample through customs. You are 'the best of the best'. You have been such a godsend in a challenging time in our lives"

  • "You have been so incredibly kind, helpful and patient for which you have my eternal gratitude………once again thank you so much…"

  • "I just wanted to say thanks for the really excellent service from Oncologica - the report arrived today, and the path there has been so smooth - we really do appreciate it!

    ….again I would add that the process has been made extremely easy for me as an administrator, for which I am also grateful!"

    Spire, Leicester

  • Louise, thank you very for all your help in getting this test done.
    Kind regards

  • "…….as for my health. My last scan is looking better and treatment is continuing, there's another treatment available in the wings thanks to Oncologica.  I heard the interview, by chance, on Newstalk with Pat Kenny. So did many of my friends. It was very accessible to the layman and most interesting.

    Again, my sincere thanks to all your friendly, helpful and efficient team" 

Ask for more Information

Click the button aside or call at +44 (0) 1223 785327 (UK)

Our Scientific Operators are at your disposal.

Latest News on cancer research

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic […]

Nobel prize for medicine goes to cancer therapy

Two scientists who discovered how to fight cancer using the body’s immune system have won the 2018 Nobel Prize for physiology or medicine. The work, by Professor James P Allison from the US and Professor Tasuku Honjo from Japan, has led to treatments for advanced, deadly skin cancer. Immune checkpoint therapy has revolutionised cancer treatment, said […]

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Oncologica contributes to a seminal study by Paul Scorer, in partnership with colleagues in the IMED Biotech Unit at AstraZeneca, who have investigated the consistency of tumour and immune cell programmed cell death ligand-1 expression, within and between tumour blocks, using the VENTANA SP263 assay. Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 […]